Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders
10 Nov 2023
Drug ApprovalGene Therapy
BCC Research Finds Innovative Technologies on the Rise for Treatment of MS & Similar Disorders. Advancements in medical tech make headway in new treatments for Multiple Sclerosis (MS), Progressive Ataxia, and other demyelinating weakness disorders.
BOSTON, Nov. 10, 2023 /PRNewswire/ -- A 2019 study cited by the National Multiple Sclerosis Society revealed that more than a million people struggle with MS in the United States alone. Globally, and when considering the myriad of general weakness disorders, that number increases drastically.
BCC's latest report, Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders, analyzes factors that have motivated treatment advancements aimed at weakness disorder patients, including the rising prevalence of syndromes related to progressive ataxia and weakness disorders due to alcohol misuse, as well as increasing prevalence of stroke, tumor, and brain degeneration.
The report digs into leading treatment options, which include:
Mesenchymal stem cells derived from the patient's own bone marrow, which have been shown to improve outcomes across multiple domains. Conducted by The Tisch MS Research Center of New YorkMS Research Center of New York, this study shows that the stem cell treatments increase gray matter volume, indicating potential neuron and cognition restoration.
Gene therapy, which has begun to emerge as a promising avenue for addressing demyelinating diseases like MS, offering potential improvements in brain repair.
Medicines like
omaveloxolone (Skyclarys), the first and only therapy sanctioned for the treatment of Friedreich's ataxia in patients 16 years and older. The FDA approved the drug in February 2023 for treatments in the US. The drug is produced by Reata Pharmaceuticals.
Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders reveals significant breakthroughs in the quest to address these rare and challenging neurodegenerative disorders, offering newfound hope to patients and their families.
Download Report Overview
For further information or to make a purchase, please get in touch with [email protected].
About BCC Research
BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts' goal is to help you make informed business decisions, free of noise and hype.
Contact Us
Corporate HQ:
BCC Research LLC
49 Walnut Park, Building 2
Wellesley, MA 02481, USA
[email protected],
+1 781-489-7301
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email [email protected] or visit www.bccresearch.com/media to request access to our library of market research.
Logo: https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg
SOURCE BCC Research LLC
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.